F.E. Shadrichev (1, 2), T. Yu. Demidova (3), N.N. Grigorieva (2, 4), A.A. Kozhevnikov (3)1) Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia; 2) City Consultative and Diagnostic Center № 1, St. Petersburg Territorial Diabetes Center, St. Petersburg, Russia; 3) Department of Endocrinology, Faculty of Medicine, Pirogov Russian National Research Medical University, Moscow, Russia; 4) St. Petersburg State University, St. Petersburg, Russia
To date, the prevalence of diabetes mellitus (DM) has already reached the level of a non-infectious pandemic. With an increase in the prevalence of diabetes, the number of associated complications, including ophthalmic ones, is increasing. Diabetic retinopathy and diabetic macular edema are the main cause of vision loss among the working-age population. Understanding of the pathogenetic processes underlying the ophthalmological complications of diabetes determines the importance of early diagnosis and the need for timely treatment aimed at maintenance of visual functions. This review provides practical information on the management of patients with diabetic retinal lesions and describes the historical way of changing the paradigm of treating diabetic macular edema from retinal laser coagulation to the current gold standard – antiangiogenic therapy.
For citations: Shadrichev F.E., Demidova T.Yu., Grigorieva N.N., Kozhevnikov A.A. Prevention of blindness in diabetes mellitus. From retinal laser coagulation to pharmacology. Farmateka. 2019;26(4):68–78. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.4.68-78
Corresponding author: Fedor E. Shadrichev, PhD, Head of the Ophthalmology Department, St. Petersburg Territorial Diabetes Center, St. Petersburg, Russia; e-mail: email@example.com
Address: 104, Siqueiros Street, St. Petersburg 194354, Russian Federation